GlassScriptPhysician profile
Guillermo J Morell
NPI 1346238268
$757.86
in general payments reported to CMS, 2019-2025
12 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.37 · 2021: $24.30 · 2022: $42.64 · 2023: $180 · 2024: $283 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $572 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $571.94 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $182.84 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $134.06 | 2021-2024 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $85.21 | 2019-2024 | Farxiga |
| Mallinckrodt Enterprises LLC | $74.99 | 2019 | |
| Ani Pharmaceuticals, INC. | $63.06 | 2023 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $48.03 | 2022-2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.29 | 2024-2025 | Jardiance |
| Vifor Pharma, INC. | $38.45 | 2022-2023 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $32.16 | 2024 | |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Cycle Pharmaceuticals INC | $17.66 | 2025 | Venxxiva |
| Merck Sharp & Dohme LLC | $16.50 | 2023 | Dificid, Prevymis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guillermo Morell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.